Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PDE2A | O00408 | 2/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10128520 | 0.93 | POLB (0.39) | POLBPDE2APDE10APTGER4TP53 | |
| SCHEMBL10128470 | 0.90 | POLB (0.49) | POLBPDE2APDE10APTGER4MAPT | |
| SCHEMBL10128854 | 0.89 | POLB (0.41) | POLBPDE2APDE10APTGER4PDK2 | |
| SCHEMBL10128895 | 0.88 | POLB (0.42) | POLBTP53MAPTKDM4EALDH1A1 | |
| SCHEMBL10128861 | 0.86 | POLB (0.39) | POLBPDE2APDE10APTGER4 | |
| SCHEMBL10128708 | 0.84 | POLB (0.39) | POLBTP53MAPTPDK2KDM4E | |
| SCHEMBL10128475 | 0.83 | POLB (0.46) | POLBPDE2APDE10APTGER4PDK2 | |
| SCHEMBL10128532 | 0.82 | POLB (0.38) | POLBPDE2APDE10AMAPTKDM4E | |
| SCHEMBL10127778 | 0.82 | POLB (0.41) | POLBKDM4EALDH1A1HPGD | |
| SCHEMBL10127842 | 0.82 | POLB (0.41) | POLBKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| US-9034486-B2 | Triazole derivative, heterocyclic compound, light-emitting element, light-emitting device, electronic device and lighting device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD (JP) | 2015-05-19 | — | — | US | disclosed |
| WO-2012017842-A1 | TRIAZOLE DERIVATIVE, HETEROCYCLIC COMPOUND, LIGHT-EMITTING ELEMENT, LIGHT-EMITTING DEVICE, ELECTRONIC DEVICE AND LIGHTING DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-02-09 | — | — | WO | disclosed |
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-02-02 | — | — | US | disclosed |
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120025697-A1 | Triazole Derivative, Heterocyclic Compound, Light-Emitting Element, Light-Emitting Device, Electronic Device and Lighting Device | HTR3D, KCNQ4, KCNQ3 | POLB 3317/4885PDE2A 3339/4885PDE10A 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.